Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
25,125
archived clinical trials in
Diabetes

A Study of the Efficacy and Safety of MK-0431D (a Fixed-dose Combination of Sitagliptin and Simvastatin) for the Treatment of Participants With Type 2 Diabetes Mellitus (T2DM) With Inadequate Glycemic Control on Metformin Monotherapy (MK-0431D-266 AM1)
A Phase III, Randomized, Double-blind, Clinical Trial to Study the Efficacy and Safety of MK-0431D (a Fixed-dose Combination [FDC] of Sitagliptin and Simvastatin) for the Treatment of Patients With Type 2 Diabetes Mellitus (T2DM) With Inadequate Glycemic Control on Metformin Monotherapy
Status: Enrolling
Updated:  8/1/2013
Clinical Research Facility
mi
from
San Antonio, TX
A Study of the Efficacy and Safety of MK-0431D (a Fixed-dose Combination of Sitagliptin and Simvastatin) for the Treatment of Participants With Type 2 Diabetes Mellitus (T2DM) With Inadequate Glycemic Control on Metformin Monotherapy (MK-0431D-266 AM1)
A Phase III, Randomized, Double-blind, Clinical Trial to Study the Efficacy and Safety of MK-0431D (a Fixed-dose Combination [FDC] of Sitagliptin and Simvastatin) for the Treatment of Patients With Type 2 Diabetes Mellitus (T2DM) With Inadequate Glycemic Control on Metformin Monotherapy
Status: Enrolling
Updated: 8/1/2013
Clinical Research Facility
mi
from
San Antonio, TX
Click here to add this to my saved trials
A Study of the Efficacy and Safety of MK-0431D (a Fixed-dose Combination of Sitagliptin and Simvastatin) for the Treatment of Participants With Type 2 Diabetes Mellitus (T2DM) With Inadequate Glycemic Control on Metformin Monotherapy (MK-0431D-266 AM1)
A Phase III, Randomized, Double-blind, Clinical Trial to Study the Efficacy and Safety of MK-0431D (a Fixed-dose Combination [FDC] of Sitagliptin and Simvastatin) for the Treatment of Patients With Type 2 Diabetes Mellitus (T2DM) With Inadequate Glycemic Control on Metformin Monotherapy
Status: Enrolling
Updated:  8/1/2013
Clinical Research Facility
mi
from
Sugar Land, TX
A Study of the Efficacy and Safety of MK-0431D (a Fixed-dose Combination of Sitagliptin and Simvastatin) for the Treatment of Participants With Type 2 Diabetes Mellitus (T2DM) With Inadequate Glycemic Control on Metformin Monotherapy (MK-0431D-266 AM1)
A Phase III, Randomized, Double-blind, Clinical Trial to Study the Efficacy and Safety of MK-0431D (a Fixed-dose Combination [FDC] of Sitagliptin and Simvastatin) for the Treatment of Patients With Type 2 Diabetes Mellitus (T2DM) With Inadequate Glycemic Control on Metformin Monotherapy
Status: Enrolling
Updated: 8/1/2013
Clinical Research Facility
mi
from
Sugar Land, TX
Click here to add this to my saved trials
A Study of the Efficacy and Safety of MK-0431D (a Fixed-dose Combination of Sitagliptin and Simvastatin) for the Treatment of Participants With Type 2 Diabetes Mellitus (T2DM) With Inadequate Glycemic Control on Metformin Monotherapy (MK-0431D-266 AM1)
A Phase III, Randomized, Double-blind, Clinical Trial to Study the Efficacy and Safety of MK-0431D (a Fixed-dose Combination [FDC] of Sitagliptin and Simvastatin) for the Treatment of Patients With Type 2 Diabetes Mellitus (T2DM) With Inadequate Glycemic Control on Metformin Monotherapy
Status: Enrolling
Updated:  8/1/2013
Clinical Research Facility
mi
from
Bountiful, UT
A Study of the Efficacy and Safety of MK-0431D (a Fixed-dose Combination of Sitagliptin and Simvastatin) for the Treatment of Participants With Type 2 Diabetes Mellitus (T2DM) With Inadequate Glycemic Control on Metformin Monotherapy (MK-0431D-266 AM1)
A Phase III, Randomized, Double-blind, Clinical Trial to Study the Efficacy and Safety of MK-0431D (a Fixed-dose Combination [FDC] of Sitagliptin and Simvastatin) for the Treatment of Patients With Type 2 Diabetes Mellitus (T2DM) With Inadequate Glycemic Control on Metformin Monotherapy
Status: Enrolling
Updated: 8/1/2013
Clinical Research Facility
mi
from
Bountiful, UT
Click here to add this to my saved trials
A Study of the Efficacy and Safety of MK-0431D (a Fixed-dose Combination of Sitagliptin and Simvastatin) for the Treatment of Participants With Type 2 Diabetes Mellitus (T2DM) With Inadequate Glycemic Control on Metformin Monotherapy (MK-0431D-266 AM1)
A Phase III, Randomized, Double-blind, Clinical Trial to Study the Efficacy and Safety of MK-0431D (a Fixed-dose Combination [FDC] of Sitagliptin and Simvastatin) for the Treatment of Patients With Type 2 Diabetes Mellitus (T2DM) With Inadequate Glycemic Control on Metformin Monotherapy
Status: Enrolling
Updated:  8/1/2013
Clinical Research Facility
mi
from
Manassas, VA
A Study of the Efficacy and Safety of MK-0431D (a Fixed-dose Combination of Sitagliptin and Simvastatin) for the Treatment of Participants With Type 2 Diabetes Mellitus (T2DM) With Inadequate Glycemic Control on Metformin Monotherapy (MK-0431D-266 AM1)
A Phase III, Randomized, Double-blind, Clinical Trial to Study the Efficacy and Safety of MK-0431D (a Fixed-dose Combination [FDC] of Sitagliptin and Simvastatin) for the Treatment of Patients With Type 2 Diabetes Mellitus (T2DM) With Inadequate Glycemic Control on Metformin Monotherapy
Status: Enrolling
Updated: 8/1/2013
Clinical Research Facility
mi
from
Manassas, VA
Click here to add this to my saved trials
A Study of the Efficacy and Safety of MK-0431D (a Fixed-dose Combination of Sitagliptin and Simvastatin) for the Treatment of Participants With Type 2 Diabetes Mellitus (T2DM) With Inadequate Glycemic Control on Metformin Monotherapy (MK-0431D-266 AM1)
A Phase III, Randomized, Double-blind, Clinical Trial to Study the Efficacy and Safety of MK-0431D (a Fixed-dose Combination [FDC] of Sitagliptin and Simvastatin) for the Treatment of Patients With Type 2 Diabetes Mellitus (T2DM) With Inadequate Glycemic Control on Metformin Monotherapy
Status: Enrolling
Updated:  8/1/2013
Clinical Research Facility
mi
from
Richmond, VA
A Study of the Efficacy and Safety of MK-0431D (a Fixed-dose Combination of Sitagliptin and Simvastatin) for the Treatment of Participants With Type 2 Diabetes Mellitus (T2DM) With Inadequate Glycemic Control on Metformin Monotherapy (MK-0431D-266 AM1)
A Phase III, Randomized, Double-blind, Clinical Trial to Study the Efficacy and Safety of MK-0431D (a Fixed-dose Combination [FDC] of Sitagliptin and Simvastatin) for the Treatment of Patients With Type 2 Diabetes Mellitus (T2DM) With Inadequate Glycemic Control on Metformin Monotherapy
Status: Enrolling
Updated: 8/1/2013
Clinical Research Facility
mi
from
Richmond, VA
Click here to add this to my saved trials
Comparative Effectiveness of Two Approaches to Diabetes Management in the Uninsured
Comparative Effectiveness of Two Community Based Diabetes Management Approaches
Status: Enrolling
Updated:  8/5/2013
OPEN M
mi
from
Akron, OH
Comparative Effectiveness of Two Approaches to Diabetes Management in the Uninsured
Comparative Effectiveness of Two Community Based Diabetes Management Approaches
Status: Enrolling
Updated: 8/5/2013
OPEN M
mi
from
Akron, OH
Click here to add this to my saved trials
Examining the Effects of Antipsychotic Medications on Insulin Sensitivity
Acute Impact of Antipsychotics on Insulin Sensitivity: A Novel Human Model
Status: Enrolling
Updated:  8/6/2013
VA San Diego Healthcare System
mi
from
San Diego, CA
Examining the Effects of Antipsychotic Medications on Insulin Sensitivity
Acute Impact of Antipsychotics on Insulin Sensitivity: A Novel Human Model
Status: Enrolling
Updated: 8/6/2013
VA San Diego Healthcare System
mi
from
San Diego, CA
Click here to add this to my saved trials
Safety, Tolerability and Efficacy of ISIS-GCGRRx in Type 2 Diabetes
A Double Blind, Placebo-Controlled, Phase 2 Study to Assess the Safety, Tolerability and Efficacy of ISIS 449884 Administered Once Weekly to Patients With Type 2 Diabetes Mellitus Being Treated With Metformin
Status: Enrolling
Updated:  8/7/2013
Isis Investigational Site
mi
from
Birmingham, AL
Safety, Tolerability and Efficacy of ISIS-GCGRRx in Type 2 Diabetes
A Double Blind, Placebo-Controlled, Phase 2 Study to Assess the Safety, Tolerability and Efficacy of ISIS 449884 Administered Once Weekly to Patients With Type 2 Diabetes Mellitus Being Treated With Metformin
Status: Enrolling
Updated: 8/7/2013
Isis Investigational Site
mi
from
Birmingham, AL
Click here to add this to my saved trials
Safety, Tolerability and Efficacy of ISIS-GCGRRx in Type 2 Diabetes
A Double Blind, Placebo-Controlled, Phase 2 Study to Assess the Safety, Tolerability and Efficacy of ISIS 449884 Administered Once Weekly to Patients With Type 2 Diabetes Mellitus Being Treated With Metformin
Status: Enrolling
Updated:  8/7/2013
Isis Investigational Site
mi
from
Anaheim, CA
Safety, Tolerability and Efficacy of ISIS-GCGRRx in Type 2 Diabetes
A Double Blind, Placebo-Controlled, Phase 2 Study to Assess the Safety, Tolerability and Efficacy of ISIS 449884 Administered Once Weekly to Patients With Type 2 Diabetes Mellitus Being Treated With Metformin
Status: Enrolling
Updated: 8/7/2013
Isis Investigational Site
mi
from
Anaheim, CA
Click here to add this to my saved trials
Safety, Tolerability and Efficacy of ISIS-GCGRRx in Type 2 Diabetes
A Double Blind, Placebo-Controlled, Phase 2 Study to Assess the Safety, Tolerability and Efficacy of ISIS 449884 Administered Once Weekly to Patients With Type 2 Diabetes Mellitus Being Treated With Metformin
Status: Enrolling
Updated:  8/7/2013
Isis Investigational Site
mi
from
Deland, FL
Safety, Tolerability and Efficacy of ISIS-GCGRRx in Type 2 Diabetes
A Double Blind, Placebo-Controlled, Phase 2 Study to Assess the Safety, Tolerability and Efficacy of ISIS 449884 Administered Once Weekly to Patients With Type 2 Diabetes Mellitus Being Treated With Metformin
Status: Enrolling
Updated: 8/7/2013
Isis Investigational Site
mi
from
Deland, FL
Click here to add this to my saved trials
Safety, Tolerability and Efficacy of ISIS-GCGRRx in Type 2 Diabetes
A Double Blind, Placebo-Controlled, Phase 2 Study to Assess the Safety, Tolerability and Efficacy of ISIS 449884 Administered Once Weekly to Patients With Type 2 Diabetes Mellitus Being Treated With Metformin
Status: Enrolling
Updated:  8/7/2013
Isis Investigational Site
mi
from
Marietta, GA
Safety, Tolerability and Efficacy of ISIS-GCGRRx in Type 2 Diabetes
A Double Blind, Placebo-Controlled, Phase 2 Study to Assess the Safety, Tolerability and Efficacy of ISIS 449884 Administered Once Weekly to Patients With Type 2 Diabetes Mellitus Being Treated With Metformin
Status: Enrolling
Updated: 8/7/2013
Isis Investigational Site
mi
from
Marietta, GA
Click here to add this to my saved trials
Safety, Tolerability and Efficacy of ISIS-GCGRRx in Type 2 Diabetes
A Double Blind, Placebo-Controlled, Phase 2 Study to Assess the Safety, Tolerability and Efficacy of ISIS 449884 Administered Once Weekly to Patients With Type 2 Diabetes Mellitus Being Treated With Metformin
Status: Enrolling
Updated:  8/7/2013
Isis Investigational Site
mi
from
Las Vegas, NV
Safety, Tolerability and Efficacy of ISIS-GCGRRx in Type 2 Diabetes
A Double Blind, Placebo-Controlled, Phase 2 Study to Assess the Safety, Tolerability and Efficacy of ISIS 449884 Administered Once Weekly to Patients With Type 2 Diabetes Mellitus Being Treated With Metformin
Status: Enrolling
Updated: 8/7/2013
Isis Investigational Site
mi
from
Las Vegas, NV
Click here to add this to my saved trials
Safety, Tolerability and Efficacy of ISIS-GCGRRx in Type 2 Diabetes
A Double Blind, Placebo-Controlled, Phase 2 Study to Assess the Safety, Tolerability and Efficacy of ISIS 449884 Administered Once Weekly to Patients With Type 2 Diabetes Mellitus Being Treated With Metformin
Status: Enrolling
Updated:  8/7/2013
Isis Investigational Site
mi
from
Cincinnati, OH
Safety, Tolerability and Efficacy of ISIS-GCGRRx in Type 2 Diabetes
A Double Blind, Placebo-Controlled, Phase 2 Study to Assess the Safety, Tolerability and Efficacy of ISIS 449884 Administered Once Weekly to Patients With Type 2 Diabetes Mellitus Being Treated With Metformin
Status: Enrolling
Updated: 8/7/2013
Isis Investigational Site
mi
from
Cincinnati, OH
Click here to add this to my saved trials
Safety, Tolerability and Efficacy of ISIS-GCGRRx in Type 2 Diabetes
A Double Blind, Placebo-Controlled, Phase 2 Study to Assess the Safety, Tolerability and Efficacy of ISIS 449884 Administered Once Weekly to Patients With Type 2 Diabetes Mellitus Being Treated With Metformin
Status: Enrolling
Updated:  8/7/2013
Isis Investigational Site
mi
from
Oklahoma City, OK
Safety, Tolerability and Efficacy of ISIS-GCGRRx in Type 2 Diabetes
A Double Blind, Placebo-Controlled, Phase 2 Study to Assess the Safety, Tolerability and Efficacy of ISIS 449884 Administered Once Weekly to Patients With Type 2 Diabetes Mellitus Being Treated With Metformin
Status: Enrolling
Updated: 8/7/2013
Isis Investigational Site
mi
from
Oklahoma City, OK
Click here to add this to my saved trials
Safety, Tolerability and Efficacy of ISIS-GCGRRx in Type 2 Diabetes
A Double Blind, Placebo-Controlled, Phase 2 Study to Assess the Safety, Tolerability and Efficacy of ISIS 449884 Administered Once Weekly to Patients With Type 2 Diabetes Mellitus Being Treated With Metformin
Status: Enrolling
Updated:  8/7/2013
Isis Investigational Site
mi
from
Eugene, OR
Safety, Tolerability and Efficacy of ISIS-GCGRRx in Type 2 Diabetes
A Double Blind, Placebo-Controlled, Phase 2 Study to Assess the Safety, Tolerability and Efficacy of ISIS 449884 Administered Once Weekly to Patients With Type 2 Diabetes Mellitus Being Treated With Metformin
Status: Enrolling
Updated: 8/7/2013
Isis Investigational Site
mi
from
Eugene, OR
Click here to add this to my saved trials
Safety, Tolerability and Efficacy of ISIS-GCGRRx in Type 2 Diabetes
A Double Blind, Placebo-Controlled, Phase 2 Study to Assess the Safety, Tolerability and Efficacy of ISIS 449884 Administered Once Weekly to Patients With Type 2 Diabetes Mellitus Being Treated With Metformin
Status: Enrolling
Updated:  8/7/2013
Isis Investigational Site
mi
from
Corpus Christi, TX
Safety, Tolerability and Efficacy of ISIS-GCGRRx in Type 2 Diabetes
A Double Blind, Placebo-Controlled, Phase 2 Study to Assess the Safety, Tolerability and Efficacy of ISIS 449884 Administered Once Weekly to Patients With Type 2 Diabetes Mellitus Being Treated With Metformin
Status: Enrolling
Updated: 8/7/2013
Isis Investigational Site
mi
from
Corpus Christi, TX
Click here to add this to my saved trials
Safety, Tolerability and Efficacy of ISIS-GCGRRx in Type 2 Diabetes
A Double Blind, Placebo-Controlled, Phase 2 Study to Assess the Safety, Tolerability and Efficacy of ISIS 449884 Administered Once Weekly to Patients With Type 2 Diabetes Mellitus Being Treated With Metformin
Status: Enrolling
Updated:  8/7/2013
Isis Investigational Site
mi
from
Salt Lake City, UT
Safety, Tolerability and Efficacy of ISIS-GCGRRx in Type 2 Diabetes
A Double Blind, Placebo-Controlled, Phase 2 Study to Assess the Safety, Tolerability and Efficacy of ISIS 449884 Administered Once Weekly to Patients With Type 2 Diabetes Mellitus Being Treated With Metformin
Status: Enrolling
Updated: 8/7/2013
Isis Investigational Site
mi
from
Salt Lake City, UT
Click here to add this to my saved trials
Safety, Tolerability and Efficacy of ISIS-GCGRRx in Type 2 Diabetes
A Double Blind, Placebo-Controlled, Phase 2 Study to Assess the Safety, Tolerability and Efficacy of ISIS 449884 Administered Once Weekly to Patients With Type 2 Diabetes Mellitus Being Treated With Metformin
Status: Enrolling
Updated:  8/7/2013
Isis Investigational Site
mi
from
Renton, WA
Safety, Tolerability and Efficacy of ISIS-GCGRRx in Type 2 Diabetes
A Double Blind, Placebo-Controlled, Phase 2 Study to Assess the Safety, Tolerability and Efficacy of ISIS 449884 Administered Once Weekly to Patients With Type 2 Diabetes Mellitus Being Treated With Metformin
Status: Enrolling
Updated: 8/7/2013
Isis Investigational Site
mi
from
Renton, WA
Click here to add this to my saved trials
Feasibility Study Assessing the Ability of an Insulin Pump-controlling Algorithm to Minimize Hypoglycemia
Feasibility Study Assessing the Ability of an Insulin Pump-controlling Algorithm to Minimize Hypoglycemia in Patients With Type 1 Diabetes in a Clinical Research Setting
Status: Enrolling
Updated:  8/8/2013
Samsum Diabetes Reserach Inst.
mi
from
Santa Barbara, CA
Feasibility Study Assessing the Ability of an Insulin Pump-controlling Algorithm to Minimize Hypoglycemia
Feasibility Study Assessing the Ability of an Insulin Pump-controlling Algorithm to Minimize Hypoglycemia in Patients With Type 1 Diabetes in a Clinical Research Setting
Status: Enrolling
Updated: 8/8/2013
Samsum Diabetes Reserach Inst.
mi
from
Santa Barbara, CA
Click here to add this to my saved trials
Regulating Efficacy and Wellness in Diabetes
Social Cognitive and Neuropsychological Influences on Physical Activity Behavior in Type II Diabetes
Status: Enrolling
Updated:  8/9/2013
University of Illinois at Urbana-Champaign
mi
from
Urbana, IL
Regulating Efficacy and Wellness in Diabetes
Social Cognitive and Neuropsychological Influences on Physical Activity Behavior in Type II Diabetes
Status: Enrolling
Updated: 8/9/2013
University of Illinois at Urbana-Champaign
mi
from
Urbana, IL
Click here to add this to my saved trials
Multiple Dose Study Of PF-05231023 In Adult Subjects Who Have Poor Lipid Control With And Without Type 2 Diabetes Mellitus
A Phase 1, Placebo-Controlled, Randomized Trial To Assess The Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Of Multiple IV Doses Of PF-05231023 In Obese Hyperlipidemic Adult Subjects With And Without Type 2 Diabetes Mellitus On A Background Of Atorvastatin
Status: Enrolling
Updated:  8/19/2013
Pfizer Investigational Site
mi
from
Los Angeles, CA
Multiple Dose Study Of PF-05231023 In Adult Subjects Who Have Poor Lipid Control With And Without Type 2 Diabetes Mellitus
A Phase 1, Placebo-Controlled, Randomized Trial To Assess The Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Of Multiple IV Doses Of PF-05231023 In Obese Hyperlipidemic Adult Subjects With And Without Type 2 Diabetes Mellitus On A Background Of Atorvastatin
Status: Enrolling
Updated: 8/19/2013
Pfizer Investigational Site
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Multiple Dose Study Of PF-05231023 In Adult Subjects Who Have Poor Lipid Control With And Without Type 2 Diabetes Mellitus
A Phase 1, Placebo-Controlled, Randomized Trial To Assess The Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Of Multiple IV Doses Of PF-05231023 In Obese Hyperlipidemic Adult Subjects With And Without Type 2 Diabetes Mellitus On A Background Of Atorvastatin
Status: Enrolling
Updated:  8/19/2013
Pfizer Investigational Site
mi
from
Atlantis, FL
Multiple Dose Study Of PF-05231023 In Adult Subjects Who Have Poor Lipid Control With And Without Type 2 Diabetes Mellitus
A Phase 1, Placebo-Controlled, Randomized Trial To Assess The Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Of Multiple IV Doses Of PF-05231023 In Obese Hyperlipidemic Adult Subjects With And Without Type 2 Diabetes Mellitus On A Background Of Atorvastatin
Status: Enrolling
Updated: 8/19/2013
Pfizer Investigational Site
mi
from
Atlantis, FL
Click here to add this to my saved trials
Multiple Dose Study Of PF-05231023 In Adult Subjects Who Have Poor Lipid Control With And Without Type 2 Diabetes Mellitus
A Phase 1, Placebo-Controlled, Randomized Trial To Assess The Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Of Multiple IV Doses Of PF-05231023 In Obese Hyperlipidemic Adult Subjects With And Without Type 2 Diabetes Mellitus On A Background Of Atorvastatin
Status: Enrolling
Updated:  8/19/2013
Pfizer Investigational Site
mi
from
Ashland, KY
Multiple Dose Study Of PF-05231023 In Adult Subjects Who Have Poor Lipid Control With And Without Type 2 Diabetes Mellitus
A Phase 1, Placebo-Controlled, Randomized Trial To Assess The Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Of Multiple IV Doses Of PF-05231023 In Obese Hyperlipidemic Adult Subjects With And Without Type 2 Diabetes Mellitus On A Background Of Atorvastatin
Status: Enrolling
Updated: 8/19/2013
Pfizer Investigational Site
mi
from
Ashland, KY
Click here to add this to my saved trials
Multiple Dose Study Of PF-05231023 In Adult Subjects Who Have Poor Lipid Control With And Without Type 2 Diabetes Mellitus
A Phase 1, Placebo-Controlled, Randomized Trial To Assess The Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Of Multiple IV Doses Of PF-05231023 In Obese Hyperlipidemic Adult Subjects With And Without Type 2 Diabetes Mellitus On A Background Of Atorvastatin
Status: Enrolling
Updated:  8/19/2013
Pfizer Investigational Site
mi
from
Duluth, MN
Multiple Dose Study Of PF-05231023 In Adult Subjects Who Have Poor Lipid Control With And Without Type 2 Diabetes Mellitus
A Phase 1, Placebo-Controlled, Randomized Trial To Assess The Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Of Multiple IV Doses Of PF-05231023 In Obese Hyperlipidemic Adult Subjects With And Without Type 2 Diabetes Mellitus On A Background Of Atorvastatin
Status: Enrolling
Updated: 8/19/2013
Pfizer Investigational Site
mi
from
Duluth, MN
Click here to add this to my saved trials
Multiple Dose Study Of PF-05231023 In Adult Subjects Who Have Poor Lipid Control With And Without Type 2 Diabetes Mellitus
A Phase 1, Placebo-Controlled, Randomized Trial To Assess The Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Of Multiple IV Doses Of PF-05231023 In Obese Hyperlipidemic Adult Subjects With And Without Type 2 Diabetes Mellitus On A Background Of Atorvastatin
Status: Enrolling
Updated:  8/19/2013
Pfizer Investigational Site
mi
from
Asheville, NC
Multiple Dose Study Of PF-05231023 In Adult Subjects Who Have Poor Lipid Control With And Without Type 2 Diabetes Mellitus
A Phase 1, Placebo-Controlled, Randomized Trial To Assess The Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Of Multiple IV Doses Of PF-05231023 In Obese Hyperlipidemic Adult Subjects With And Without Type 2 Diabetes Mellitus On A Background Of Atorvastatin
Status: Enrolling
Updated: 8/19/2013
Pfizer Investigational Site
mi
from
Asheville, NC
Click here to add this to my saved trials
Multiple Dose Study Of PF-05231023 In Adult Subjects Who Have Poor Lipid Control With And Without Type 2 Diabetes Mellitus
A Phase 1, Placebo-Controlled, Randomized Trial To Assess The Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Of Multiple IV Doses Of PF-05231023 In Obese Hyperlipidemic Adult Subjects With And Without Type 2 Diabetes Mellitus On A Background Of Atorvastatin
Status: Enrolling
Updated:  8/19/2013
Pfizer Investigational Site
mi
from
Akron, OH
Multiple Dose Study Of PF-05231023 In Adult Subjects Who Have Poor Lipid Control With And Without Type 2 Diabetes Mellitus
A Phase 1, Placebo-Controlled, Randomized Trial To Assess The Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Of Multiple IV Doses Of PF-05231023 In Obese Hyperlipidemic Adult Subjects With And Without Type 2 Diabetes Mellitus On A Background Of Atorvastatin
Status: Enrolling
Updated: 8/19/2013
Pfizer Investigational Site
mi
from
Akron, OH
Click here to add this to my saved trials
Multiple Dose Study Of PF-05231023 In Adult Subjects Who Have Poor Lipid Control With And Without Type 2 Diabetes Mellitus
A Phase 1, Placebo-Controlled, Randomized Trial To Assess The Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Of Multiple IV Doses Of PF-05231023 In Obese Hyperlipidemic Adult Subjects With And Without Type 2 Diabetes Mellitus On A Background Of Atorvastatin
Status: Enrolling
Updated:  8/19/2013
Pfizer Investigational Site
mi
from
Houston, TX
Multiple Dose Study Of PF-05231023 In Adult Subjects Who Have Poor Lipid Control With And Without Type 2 Diabetes Mellitus
A Phase 1, Placebo-Controlled, Randomized Trial To Assess The Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Of Multiple IV Doses Of PF-05231023 In Obese Hyperlipidemic Adult Subjects With And Without Type 2 Diabetes Mellitus On A Background Of Atorvastatin
Status: Enrolling
Updated: 8/19/2013
Pfizer Investigational Site
mi
from
Houston, TX
Click here to add this to my saved trials
A Study to Evaluate the Effect of Ranolazine on Postprandial Glucagon in Subjects With Type 2 Diabetes.
A Phase 1, Randomized, Single-blind, Placebo-controlled, Multiple-dose, Two-sequence, Cross-over Study to Evaluate the Effect of Ranolazine on Glucagon Secretion in Subjects With Type 2 Diabetes Mellitus, Followed by An Open-label, Single Dose, Exenatide Active-control Period
Status: Enrolling
Updated:  8/20/2013
Profil Institute for Clinical Research
mi
from
Chula Vista, CA
A Study to Evaluate the Effect of Ranolazine on Postprandial Glucagon in Subjects With Type 2 Diabetes.
A Phase 1, Randomized, Single-blind, Placebo-controlled, Multiple-dose, Two-sequence, Cross-over Study to Evaluate the Effect of Ranolazine on Glucagon Secretion in Subjects With Type 2 Diabetes Mellitus, Followed by An Open-label, Single Dose, Exenatide Active-control Period
Status: Enrolling
Updated: 8/20/2013
Profil Institute for Clinical Research
mi
from
Chula Vista, CA
Click here to add this to my saved trials
A Study to Evaluate the Effect of Ranolazine on Postprandial Glucagon in Subjects With Type 2 Diabetes.
A Phase 1, Randomized, Single-blind, Placebo-controlled, Multiple-dose, Two-sequence, Cross-over Study to Evaluate the Effect of Ranolazine on Glucagon Secretion in Subjects With Type 2 Diabetes Mellitus, Followed by An Open-label, Single Dose, Exenatide Active-control Period
Status: Enrolling
Updated:  8/20/2013
SeaView Research Inc.
mi
from
Miami, FL
A Study to Evaluate the Effect of Ranolazine on Postprandial Glucagon in Subjects With Type 2 Diabetes.
A Phase 1, Randomized, Single-blind, Placebo-controlled, Multiple-dose, Two-sequence, Cross-over Study to Evaluate the Effect of Ranolazine on Glucagon Secretion in Subjects With Type 2 Diabetes Mellitus, Followed by An Open-label, Single Dose, Exenatide Active-control Period
Status: Enrolling
Updated: 8/20/2013
SeaView Research Inc.
mi
from
Miami, FL
Click here to add this to my saved trials
A Study to Evaluate the Effect of Ranolazine on Postprandial Glucagon in Subjects With Type 2 Diabetes.
A Phase 1, Randomized, Single-blind, Placebo-controlled, Multiple-dose, Two-sequence, Cross-over Study to Evaluate the Effect of Ranolazine on Glucagon Secretion in Subjects With Type 2 Diabetes Mellitus, Followed by An Open-label, Single Dose, Exenatide Active-control Period
Status: Enrolling
Updated:  8/20/2013
Translational Research Institute-Florida Hospital
mi
from
Orlando, FL
A Study to Evaluate the Effect of Ranolazine on Postprandial Glucagon in Subjects With Type 2 Diabetes.
A Phase 1, Randomized, Single-blind, Placebo-controlled, Multiple-dose, Two-sequence, Cross-over Study to Evaluate the Effect of Ranolazine on Glucagon Secretion in Subjects With Type 2 Diabetes Mellitus, Followed by An Open-label, Single Dose, Exenatide Active-control Period
Status: Enrolling
Updated: 8/20/2013
Translational Research Institute-Florida Hospital
mi
from
Orlando, FL
Click here to add this to my saved trials
Study to Investigate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of GSK2330672 in Type 2 Diabetes Patients Taking Metformin
A Randomized, Double-blind (Sponsor Unblinded), Placebo Controlled, Repeat Dose Study Investigating Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of GSK2330672 in Type 2 Diabetes Patients Taking Metformin
Status: Enrolling
Updated:  8/22/2013
GSK Investigational Site
mi
from
Jacksonville, FL
Study to Investigate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of GSK2330672 in Type 2 Diabetes Patients Taking Metformin
A Randomized, Double-blind (Sponsor Unblinded), Placebo Controlled, Repeat Dose Study Investigating Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of GSK2330672 in Type 2 Diabetes Patients Taking Metformin
Status: Enrolling
Updated: 8/22/2013
GSK Investigational Site
mi
from
Jacksonville, FL
Click here to add this to my saved trials
Comparing Visual Acuity Measurements (How Well You Can See) Using a Standard ETDRS Chart & a Handheld ETDRS Chart
Prospective Determination of Agreement Between Standard ETDRS (Early Treatment Diabetic Retinopathy Study) Chart and Handheld Illuminated ETDRS Equivalent Chart in Eyes With Retinal Pathology
Status: Enrolling
Updated:  8/26/2013
Mid Atlantic Retina- Wills Eye Institute
mi
from
Philadelphia, PA
Comparing Visual Acuity Measurements (How Well You Can See) Using a Standard ETDRS Chart & a Handheld ETDRS Chart
Prospective Determination of Agreement Between Standard ETDRS (Early Treatment Diabetic Retinopathy Study) Chart and Handheld Illuminated ETDRS Equivalent Chart in Eyes With Retinal Pathology
Status: Enrolling
Updated: 8/26/2013
Mid Atlantic Retina- Wills Eye Institute
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Gestational Diabetes Mellitus and Implications for Cardiovascular Disease Risk
Gestational Diabetes Mellitus and Implications for Cardiovascular Disease Risk
Status: Enrolling
Updated:  8/28/2013
Brigham and Women's Hospital, Massachusetts General Hospital
mi
from
Boston, MA
Gestational Diabetes Mellitus and Implications for Cardiovascular Disease Risk
Gestational Diabetes Mellitus and Implications for Cardiovascular Disease Risk
Status: Enrolling
Updated: 8/28/2013
Brigham and Women's Hospital, Massachusetts General Hospital
mi
from
Boston, MA
Click here to add this to my saved trials
Gestational Diabetes Mellitus and Implications for Cardiovascular Disease Risk
Gestational Diabetes Mellitus and Implications for Cardiovascular Disease Risk
Status: Enrolling
Updated:  8/28/2013
Brigham and Women's Hosp
mi
from
Boston, MA
Gestational Diabetes Mellitus and Implications for Cardiovascular Disease Risk
Gestational Diabetes Mellitus and Implications for Cardiovascular Disease Risk
Status: Enrolling
Updated: 8/28/2013
Brigham and Women's Hosp
mi
from
Boston, MA
Click here to add this to my saved trials
Gestational Diabetes Mellitus and Cardiovascular Disease: The Role of Vascular Dysfunction
Gestational Diabetes Mellitus and Cardiovascular Disease: The Role of Vascular Dysfunction
Status: Enrolling
Updated:  8/28/2013
Brigham and Women's Hospital, Massachusetts General Hospital
mi
from
Boston, MA
Gestational Diabetes Mellitus and Cardiovascular Disease: The Role of Vascular Dysfunction
Gestational Diabetes Mellitus and Cardiovascular Disease: The Role of Vascular Dysfunction
Status: Enrolling
Updated: 8/28/2013
Brigham and Women's Hospital, Massachusetts General Hospital
mi
from
Boston, MA
Click here to add this to my saved trials
A 16 Weeks Study on Efficacy and Safety of Two Doses of Empagliflozin (BI 10773) (Once Daily Versus Twice Daily) in Patients With Type 2 Diabetes Mellitus and Preexisting Metformin Therapy
A Randomised, Double Blind, Placebo Controlled, Parallel Group Efficacy and Safety Study of Oral Administration of Empagliflozin Twice Daily Versus Once Daily in Two Different Daily Doses Over 16 Weeks as add-on Therapy to a Twice Daily Dosing Regimen of Metformin in Patients With Type 2 Diabetes Mellitus and Insufficient Glycaemic Control
Status: Enrolling
Updated:  8/29/2013
205.452.01198 Boehringer Ingelheim Investigational Site
mi
from
Florence, AL
A 16 Weeks Study on Efficacy and Safety of Two Doses of Empagliflozin (BI 10773) (Once Daily Versus Twice Daily) in Patients With Type 2 Diabetes Mellitus and Preexisting Metformin Therapy
A Randomised, Double Blind, Placebo Controlled, Parallel Group Efficacy and Safety Study of Oral Administration of Empagliflozin Twice Daily Versus Once Daily in Two Different Daily Doses Over 16 Weeks as add-on Therapy to a Twice Daily Dosing Regimen of Metformin in Patients With Type 2 Diabetes Mellitus and Insufficient Glycaemic Control
Status: Enrolling
Updated: 8/29/2013
205.452.01198 Boehringer Ingelheim Investigational Site
mi
from
Florence, AL
Click here to add this to my saved trials
A 16 Weeks Study on Efficacy and Safety of Two Doses of Empagliflozin (BI 10773) (Once Daily Versus Twice Daily) in Patients With Type 2 Diabetes Mellitus and Preexisting Metformin Therapy
A Randomised, Double Blind, Placebo Controlled, Parallel Group Efficacy and Safety Study of Oral Administration of Empagliflozin Twice Daily Versus Once Daily in Two Different Daily Doses Over 16 Weeks as add-on Therapy to a Twice Daily Dosing Regimen of Metformin in Patients With Type 2 Diabetes Mellitus and Insufficient Glycaemic Control
Status: Enrolling
Updated:  8/29/2013
1200.75.10034 Boehringer Ingelheim Investigational Site
mi
from
Jonesboro, AR
A 16 Weeks Study on Efficacy and Safety of Two Doses of Empagliflozin (BI 10773) (Once Daily Versus Twice Daily) in Patients With Type 2 Diabetes Mellitus and Preexisting Metformin Therapy
A Randomised, Double Blind, Placebo Controlled, Parallel Group Efficacy and Safety Study of Oral Administration of Empagliflozin Twice Daily Versus Once Daily in Two Different Daily Doses Over 16 Weeks as add-on Therapy to a Twice Daily Dosing Regimen of Metformin in Patients With Type 2 Diabetes Mellitus and Insufficient Glycaemic Control
Status: Enrolling
Updated: 8/29/2013
1200.75.10034 Boehringer Ingelheim Investigational Site
mi
from
Jonesboro, AR
Click here to add this to my saved trials
A 16 Weeks Study on Efficacy and Safety of Two Doses of Empagliflozin (BI 10773) (Once Daily Versus Twice Daily) in Patients With Type 2 Diabetes Mellitus and Preexisting Metformin Therapy
A Randomised, Double Blind, Placebo Controlled, Parallel Group Efficacy and Safety Study of Oral Administration of Empagliflozin Twice Daily Versus Once Daily in Two Different Daily Doses Over 16 Weeks as add-on Therapy to a Twice Daily Dosing Regimen of Metformin in Patients With Type 2 Diabetes Mellitus and Insufficient Glycaemic Control
Status: Enrolling
Updated:  8/29/2013
205.452.01339 Boehringer Ingelheim Investigational Site
mi
from
Lomita, CA
A 16 Weeks Study on Efficacy and Safety of Two Doses of Empagliflozin (BI 10773) (Once Daily Versus Twice Daily) in Patients With Type 2 Diabetes Mellitus and Preexisting Metformin Therapy
A Randomised, Double Blind, Placebo Controlled, Parallel Group Efficacy and Safety Study of Oral Administration of Empagliflozin Twice Daily Versus Once Daily in Two Different Daily Doses Over 16 Weeks as add-on Therapy to a Twice Daily Dosing Regimen of Metformin in Patients With Type 2 Diabetes Mellitus and Insufficient Glycaemic Control
Status: Enrolling
Updated: 8/29/2013
205.452.01339 Boehringer Ingelheim Investigational Site
mi
from
Lomita, CA
Click here to add this to my saved trials
A 16 Weeks Study on Efficacy and Safety of Two Doses of Empagliflozin (BI 10773) (Once Daily Versus Twice Daily) in Patients With Type 2 Diabetes Mellitus and Preexisting Metformin Therapy
A Randomised, Double Blind, Placebo Controlled, Parallel Group Efficacy and Safety Study of Oral Administration of Empagliflozin Twice Daily Versus Once Daily in Two Different Daily Doses Over 16 Weeks as add-on Therapy to a Twice Daily Dosing Regimen of Metformin in Patients With Type 2 Diabetes Mellitus and Insufficient Glycaemic Control
Status: Enrolling
Updated:  8/29/2013
Boehringer Ingelheim Investigational Site
mi
from
Los Angeles, CA
A 16 Weeks Study on Efficacy and Safety of Two Doses of Empagliflozin (BI 10773) (Once Daily Versus Twice Daily) in Patients With Type 2 Diabetes Mellitus and Preexisting Metformin Therapy
A Randomised, Double Blind, Placebo Controlled, Parallel Group Efficacy and Safety Study of Oral Administration of Empagliflozin Twice Daily Versus Once Daily in Two Different Daily Doses Over 16 Weeks as add-on Therapy to a Twice Daily Dosing Regimen of Metformin in Patients With Type 2 Diabetes Mellitus and Insufficient Glycaemic Control
Status: Enrolling
Updated: 8/29/2013
Boehringer Ingelheim Investigational Site
mi
from
Los Angeles, CA
Click here to add this to my saved trials
A 16 Weeks Study on Efficacy and Safety of Two Doses of Empagliflozin (BI 10773) (Once Daily Versus Twice Daily) in Patients With Type 2 Diabetes Mellitus and Preexisting Metformin Therapy
A Randomised, Double Blind, Placebo Controlled, Parallel Group Efficacy and Safety Study of Oral Administration of Empagliflozin Twice Daily Versus Once Daily in Two Different Daily Doses Over 16 Weeks as add-on Therapy to a Twice Daily Dosing Regimen of Metformin in Patients With Type 2 Diabetes Mellitus and Insufficient Glycaemic Control
Status: Enrolling
Updated:  8/29/2013
205.452.01089 Boehringer Ingelheim Investigational Site
mi
from
Rancho Cucamonga, CA
A 16 Weeks Study on Efficacy and Safety of Two Doses of Empagliflozin (BI 10773) (Once Daily Versus Twice Daily) in Patients With Type 2 Diabetes Mellitus and Preexisting Metformin Therapy
A Randomised, Double Blind, Placebo Controlled, Parallel Group Efficacy and Safety Study of Oral Administration of Empagliflozin Twice Daily Versus Once Daily in Two Different Daily Doses Over 16 Weeks as add-on Therapy to a Twice Daily Dosing Regimen of Metformin in Patients With Type 2 Diabetes Mellitus and Insufficient Glycaemic Control
Status: Enrolling
Updated: 8/29/2013
205.452.01089 Boehringer Ingelheim Investigational Site
mi
from
Rancho Cucamonga, CA
Click here to add this to my saved trials
A 16 Weeks Study on Efficacy and Safety of Two Doses of Empagliflozin (BI 10773) (Once Daily Versus Twice Daily) in Patients With Type 2 Diabetes Mellitus and Preexisting Metformin Therapy
A Randomised, Double Blind, Placebo Controlled, Parallel Group Efficacy and Safety Study of Oral Administration of Empagliflozin Twice Daily Versus Once Daily in Two Different Daily Doses Over 16 Weeks as add-on Therapy to a Twice Daily Dosing Regimen of Metformin in Patients With Type 2 Diabetes Mellitus and Insufficient Glycaemic Control
Status: Enrolling
Updated:  8/29/2013
1245.28.10003 Boehringer Ingelheim Investigational Site
mi
from
Sacramento, CA
A 16 Weeks Study on Efficacy and Safety of Two Doses of Empagliflozin (BI 10773) (Once Daily Versus Twice Daily) in Patients With Type 2 Diabetes Mellitus and Preexisting Metformin Therapy
A Randomised, Double Blind, Placebo Controlled, Parallel Group Efficacy and Safety Study of Oral Administration of Empagliflozin Twice Daily Versus Once Daily in Two Different Daily Doses Over 16 Weeks as add-on Therapy to a Twice Daily Dosing Regimen of Metformin in Patients With Type 2 Diabetes Mellitus and Insufficient Glycaemic Control
Status: Enrolling
Updated: 8/29/2013
1245.28.10003 Boehringer Ingelheim Investigational Site
mi
from
Sacramento, CA
Click here to add this to my saved trials
A 16 Weeks Study on Efficacy and Safety of Two Doses of Empagliflozin (BI 10773) (Once Daily Versus Twice Daily) in Patients With Type 2 Diabetes Mellitus and Preexisting Metformin Therapy
A Randomised, Double Blind, Placebo Controlled, Parallel Group Efficacy and Safety Study of Oral Administration of Empagliflozin Twice Daily Versus Once Daily in Two Different Daily Doses Over 16 Weeks as add-on Therapy to a Twice Daily Dosing Regimen of Metformin in Patients With Type 2 Diabetes Mellitus and Insufficient Glycaemic Control
Status: Enrolling
Updated:  8/29/2013
1245.28.10021 Boehringer Ingelheim Investigational Site
mi
from
West Hills, CA
A 16 Weeks Study on Efficacy and Safety of Two Doses of Empagliflozin (BI 10773) (Once Daily Versus Twice Daily) in Patients With Type 2 Diabetes Mellitus and Preexisting Metformin Therapy
A Randomised, Double Blind, Placebo Controlled, Parallel Group Efficacy and Safety Study of Oral Administration of Empagliflozin Twice Daily Versus Once Daily in Two Different Daily Doses Over 16 Weeks as add-on Therapy to a Twice Daily Dosing Regimen of Metformin in Patients With Type 2 Diabetes Mellitus and Insufficient Glycaemic Control
Status: Enrolling
Updated: 8/29/2013
1245.28.10021 Boehringer Ingelheim Investigational Site
mi
from
West Hills, CA
Click here to add this to my saved trials
A 16 Weeks Study on Efficacy and Safety of Two Doses of Empagliflozin (BI 10773) (Once Daily Versus Twice Daily) in Patients With Type 2 Diabetes Mellitus and Preexisting Metformin Therapy
A Randomised, Double Blind, Placebo Controlled, Parallel Group Efficacy and Safety Study of Oral Administration of Empagliflozin Twice Daily Versus Once Daily in Two Different Daily Doses Over 16 Weeks as add-on Therapy to a Twice Daily Dosing Regimen of Metformin in Patients With Type 2 Diabetes Mellitus and Insufficient Glycaemic Control
Status: Enrolling
Updated:  8/29/2013
205.452.01072 Boehringer Ingelheim Investigational Site
mi
from
Norwalk, CT
A 16 Weeks Study on Efficacy and Safety of Two Doses of Empagliflozin (BI 10773) (Once Daily Versus Twice Daily) in Patients With Type 2 Diabetes Mellitus and Preexisting Metformin Therapy
A Randomised, Double Blind, Placebo Controlled, Parallel Group Efficacy and Safety Study of Oral Administration of Empagliflozin Twice Daily Versus Once Daily in Two Different Daily Doses Over 16 Weeks as add-on Therapy to a Twice Daily Dosing Regimen of Metformin in Patients With Type 2 Diabetes Mellitus and Insufficient Glycaemic Control
Status: Enrolling
Updated: 8/29/2013
205.452.01072 Boehringer Ingelheim Investigational Site
mi
from
Norwalk, CT
Click here to add this to my saved trials
A 16 Weeks Study on Efficacy and Safety of Two Doses of Empagliflozin (BI 10773) (Once Daily Versus Twice Daily) in Patients With Type 2 Diabetes Mellitus and Preexisting Metformin Therapy
A Randomised, Double Blind, Placebo Controlled, Parallel Group Efficacy and Safety Study of Oral Administration of Empagliflozin Twice Daily Versus Once Daily in Two Different Daily Doses Over 16 Weeks as add-on Therapy to a Twice Daily Dosing Regimen of Metformin in Patients With Type 2 Diabetes Mellitus and Insufficient Glycaemic Control
Status: Enrolling
Updated:  8/29/2013
205.452.01109 Boehringer Ingelheim Investigational Site
mi
from
Waterbury, CT
A 16 Weeks Study on Efficacy and Safety of Two Doses of Empagliflozin (BI 10773) (Once Daily Versus Twice Daily) in Patients With Type 2 Diabetes Mellitus and Preexisting Metformin Therapy
A Randomised, Double Blind, Placebo Controlled, Parallel Group Efficacy and Safety Study of Oral Administration of Empagliflozin Twice Daily Versus Once Daily in Two Different Daily Doses Over 16 Weeks as add-on Therapy to a Twice Daily Dosing Regimen of Metformin in Patients With Type 2 Diabetes Mellitus and Insufficient Glycaemic Control
Status: Enrolling
Updated: 8/29/2013
205.452.01109 Boehringer Ingelheim Investigational Site
mi
from
Waterbury, CT
Click here to add this to my saved trials
A 16 Weeks Study on Efficacy and Safety of Two Doses of Empagliflozin (BI 10773) (Once Daily Versus Twice Daily) in Patients With Type 2 Diabetes Mellitus and Preexisting Metformin Therapy
A Randomised, Double Blind, Placebo Controlled, Parallel Group Efficacy and Safety Study of Oral Administration of Empagliflozin Twice Daily Versus Once Daily in Two Different Daily Doses Over 16 Weeks as add-on Therapy to a Twice Daily Dosing Regimen of Metformin in Patients With Type 2 Diabetes Mellitus and Insufficient Glycaemic Control
Status: Enrolling
Updated:  8/29/2013
1245.25.10094 Boehringer Ingelheim Investigational Site
mi
from
Bradenton, FL
A 16 Weeks Study on Efficacy and Safety of Two Doses of Empagliflozin (BI 10773) (Once Daily Versus Twice Daily) in Patients With Type 2 Diabetes Mellitus and Preexisting Metformin Therapy
A Randomised, Double Blind, Placebo Controlled, Parallel Group Efficacy and Safety Study of Oral Administration of Empagliflozin Twice Daily Versus Once Daily in Two Different Daily Doses Over 16 Weeks as add-on Therapy to a Twice Daily Dosing Regimen of Metformin in Patients With Type 2 Diabetes Mellitus and Insufficient Glycaemic Control
Status: Enrolling
Updated: 8/29/2013
1245.25.10094 Boehringer Ingelheim Investigational Site
mi
from
Bradenton, FL
Click here to add this to my saved trials
A 16 Weeks Study on Efficacy and Safety of Two Doses of Empagliflozin (BI 10773) (Once Daily Versus Twice Daily) in Patients With Type 2 Diabetes Mellitus and Preexisting Metformin Therapy
A Randomised, Double Blind, Placebo Controlled, Parallel Group Efficacy and Safety Study of Oral Administration of Empagliflozin Twice Daily Versus Once Daily in Two Different Daily Doses Over 16 Weeks as add-on Therapy to a Twice Daily Dosing Regimen of Metformin in Patients With Type 2 Diabetes Mellitus and Insufficient Glycaemic Control
Status: Enrolling
Updated:  8/29/2013
1218.74.01156 Boehringer Ingelheim Investigational Site
mi
from
Davie, FL
A 16 Weeks Study on Efficacy and Safety of Two Doses of Empagliflozin (BI 10773) (Once Daily Versus Twice Daily) in Patients With Type 2 Diabetes Mellitus and Preexisting Metformin Therapy
A Randomised, Double Blind, Placebo Controlled, Parallel Group Efficacy and Safety Study of Oral Administration of Empagliflozin Twice Daily Versus Once Daily in Two Different Daily Doses Over 16 Weeks as add-on Therapy to a Twice Daily Dosing Regimen of Metformin in Patients With Type 2 Diabetes Mellitus and Insufficient Glycaemic Control
Status: Enrolling
Updated: 8/29/2013
1218.74.01156 Boehringer Ingelheim Investigational Site
mi
from
Davie, FL
Click here to add this to my saved trials
A 16 Weeks Study on Efficacy and Safety of Two Doses of Empagliflozin (BI 10773) (Once Daily Versus Twice Daily) in Patients With Type 2 Diabetes Mellitus and Preexisting Metformin Therapy
A Randomised, Double Blind, Placebo Controlled, Parallel Group Efficacy and Safety Study of Oral Administration of Empagliflozin Twice Daily Versus Once Daily in Two Different Daily Doses Over 16 Weeks as add-on Therapy to a Twice Daily Dosing Regimen of Metformin in Patients With Type 2 Diabetes Mellitus and Insufficient Glycaemic Control
Status: Enrolling
Updated:  8/29/2013
Boehringer Ingelheim Investigational Site
mi
from
Jacksonville, FL
A 16 Weeks Study on Efficacy and Safety of Two Doses of Empagliflozin (BI 10773) (Once Daily Versus Twice Daily) in Patients With Type 2 Diabetes Mellitus and Preexisting Metformin Therapy
A Randomised, Double Blind, Placebo Controlled, Parallel Group Efficacy and Safety Study of Oral Administration of Empagliflozin Twice Daily Versus Once Daily in Two Different Daily Doses Over 16 Weeks as add-on Therapy to a Twice Daily Dosing Regimen of Metformin in Patients With Type 2 Diabetes Mellitus and Insufficient Glycaemic Control
Status: Enrolling
Updated: 8/29/2013
Boehringer Ingelheim Investigational Site
mi
from
Jacksonville, FL
Click here to add this to my saved trials
A 16 Weeks Study on Efficacy and Safety of Two Doses of Empagliflozin (BI 10773) (Once Daily Versus Twice Daily) in Patients With Type 2 Diabetes Mellitus and Preexisting Metformin Therapy
A Randomised, Double Blind, Placebo Controlled, Parallel Group Efficacy and Safety Study of Oral Administration of Empagliflozin Twice Daily Versus Once Daily in Two Different Daily Doses Over 16 Weeks as add-on Therapy to a Twice Daily Dosing Regimen of Metformin in Patients With Type 2 Diabetes Mellitus and Insufficient Glycaemic Control
Status: Enrolling
Updated:  8/29/2013
Boehringer Ingelheim Investigational Site
mi
from
Miami, FL
A 16 Weeks Study on Efficacy and Safety of Two Doses of Empagliflozin (BI 10773) (Once Daily Versus Twice Daily) in Patients With Type 2 Diabetes Mellitus and Preexisting Metformin Therapy
A Randomised, Double Blind, Placebo Controlled, Parallel Group Efficacy and Safety Study of Oral Administration of Empagliflozin Twice Daily Versus Once Daily in Two Different Daily Doses Over 16 Weeks as add-on Therapy to a Twice Daily Dosing Regimen of Metformin in Patients With Type 2 Diabetes Mellitus and Insufficient Glycaemic Control
Status: Enrolling
Updated: 8/29/2013
Boehringer Ingelheim Investigational Site
mi
from
Miami, FL
Click here to add this to my saved trials
A 16 Weeks Study on Efficacy and Safety of Two Doses of Empagliflozin (BI 10773) (Once Daily Versus Twice Daily) in Patients With Type 2 Diabetes Mellitus and Preexisting Metformin Therapy
A Randomised, Double Blind, Placebo Controlled, Parallel Group Efficacy and Safety Study of Oral Administration of Empagliflozin Twice Daily Versus Once Daily in Two Different Daily Doses Over 16 Weeks as add-on Therapy to a Twice Daily Dosing Regimen of Metformin in Patients With Type 2 Diabetes Mellitus and Insufficient Glycaemic Control
Status: Enrolling
Updated:  8/29/2013
1160.129.32884 Boehringer Ingelheim Investigational Site
mi
from
Oakland Park, FL
A 16 Weeks Study on Efficacy and Safety of Two Doses of Empagliflozin (BI 10773) (Once Daily Versus Twice Daily) in Patients With Type 2 Diabetes Mellitus and Preexisting Metformin Therapy
A Randomised, Double Blind, Placebo Controlled, Parallel Group Efficacy and Safety Study of Oral Administration of Empagliflozin Twice Daily Versus Once Daily in Two Different Daily Doses Over 16 Weeks as add-on Therapy to a Twice Daily Dosing Regimen of Metformin in Patients With Type 2 Diabetes Mellitus and Insufficient Glycaemic Control
Status: Enrolling
Updated: 8/29/2013
1160.129.32884 Boehringer Ingelheim Investigational Site
mi
from
Oakland Park, FL
Click here to add this to my saved trials
A 16 Weeks Study on Efficacy and Safety of Two Doses of Empagliflozin (BI 10773) (Once Daily Versus Twice Daily) in Patients With Type 2 Diabetes Mellitus and Preexisting Metformin Therapy
A Randomised, Double Blind, Placebo Controlled, Parallel Group Efficacy and Safety Study of Oral Administration of Empagliflozin Twice Daily Versus Once Daily in Two Different Daily Doses Over 16 Weeks as add-on Therapy to a Twice Daily Dosing Regimen of Metformin in Patients With Type 2 Diabetes Mellitus and Insufficient Glycaemic Control
Status: Enrolling
Updated:  8/29/2013
1218.74.01104 Boehringer Ingelheim Investigational Site
mi
from
Palm Harbor, FL
A 16 Weeks Study on Efficacy and Safety of Two Doses of Empagliflozin (BI 10773) (Once Daily Versus Twice Daily) in Patients With Type 2 Diabetes Mellitus and Preexisting Metformin Therapy
A Randomised, Double Blind, Placebo Controlled, Parallel Group Efficacy and Safety Study of Oral Administration of Empagliflozin Twice Daily Versus Once Daily in Two Different Daily Doses Over 16 Weeks as add-on Therapy to a Twice Daily Dosing Regimen of Metformin in Patients With Type 2 Diabetes Mellitus and Insufficient Glycaemic Control
Status: Enrolling
Updated: 8/29/2013
1218.74.01104 Boehringer Ingelheim Investigational Site
mi
from
Palm Harbor, FL
Click here to add this to my saved trials